Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

C. Rolfo, R. Ruiz, E. Giovannetti, I. Gil-Bazo, A. Russo, F. Passiglia, M. Giallombardo, M. Peeters, L. Raez

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1493-1500
Journal	Expert Opinion on Investigational Drugs
Volume	24
Issue number	11
DOIs	https://doi.org/10.1517/13543784.2015.1096344
Publication status	Published - 2015

Access to Document

@article{ada10761b0e14a74a547fb8a335dcda1,

title = "Entrectinib: a potent new TRK, ROS1, and ALK inhibitor",

author = "C. Rolfo and R. Ruiz and E. Giovannetti and I. Gil-Bazo and A. Russo and F. Passiglia and M. Giallombardo and M. Peeters and L. Raez",

year = "2015",

doi = "10.1517/13543784.2015.1096344",

language = "Undefined/Unknown",

volume = "24",

pages = "1493--1500",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

AU - Rolfo, C.

AU - Ruiz, R.

AU - Giovannetti, E.

AU - Gil-Bazo, I.

AU - Russo, A.

AU - Passiglia, F.

AU - Giallombardo, M.

AU - Peeters, M.

AU - Raez, L.

PY - 2015

Y1 - 2015

U2 - 10.1517/13543784.2015.1096344

DO - 10.1517/13543784.2015.1096344

M3 - Article

C2 - 26457764

VL - 24

SP - 1493

EP - 1500

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -